GlassScriptPhysician profile
Arezou Fatemi
NPI 1194803445
$1,993.39
in general payments reported to CMS, 2019-2025
26 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $124 · 2021: $198 · 2022: $331 · 2023: $547 · 2024: $472 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,210.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $336.72 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Abbvie INC. | $274.86 | 2021-2024 | |
| Novo Nordisk INC | $218.30 | 2020-2023 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $174.57 | 2019-2025 | Veozah |
| Lilly USA, LLC | $109.32 | 2021-2024 | Mounjaro, Jardiance |
| Pfizer INC. | $108.24 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $93.82 | 2021-2023 | Rexulti |
| Inspire Medical Systems, INC. | $93.59 | 2024-2025 | Inspire |
| Amgen INC. | $78.44 | 2019-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $67.37 | 2019-2024 | Farxiga |
| Dexcom, INC. | $59.95 | 2022-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $52.28 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Linus Health, INC. | $37.46 | 2022-2023 | |
| Medtronic, INC. | $33.75 | 2024 | Intellis Adaptivestim, Interstim |
| Glaxosmithkline, LLC. | $30.70 | 2020-2023 | Shingrix |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $29.93 | 2021-2023 | |
| Gilead Sciences, INC. | $29.07 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $27.78 | 2025 | Neffy |
| Exact Sciences Corporation | $26.61 | 2023-2024 | Cologuard Collection Kit |
| Philips North America LLC | $18.18 | 2024 | (Ck7) Extended Holter |
| Amarin Pharma, INC. | $17.07 | 2022 | |
| Neos Therapeutics, LP | $16.32 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.00 | 2023 | |
| Janssen Pharmaceuticals, INC | $15.11 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.59 | 2023 | Quviviq |
| Ultragenyx Pharmaceutical INC. | $13.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arezou Fatemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.